tiprankstipranks
Austco Healthcare Limited (AU:AHC)
ASX:AHC
Australian Market

Austco Healthcare Limited (AHC) AI Stock Analysis

8 Followers

Top Page

AU:AHC

Austco Healthcare Limited

(Sydney:AHC)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 5.2)
Rating:63Neutral
Price Target:
AU$0.41
▲(20.59% Upside)
Action:ReiteratedDate:02/07/26
Overall score reflects strong financial health led by low leverage and solid revenue growth, partially offset by margin compression and slowing free cash flow growth. Technical indicators are a notable drag due to a clear downtrend (price below key moving averages, negative MACD). Valuation is neither compellingly cheap nor clearly expensive based on the provided P/E, with no dividend yield data to add support.
Positive Factors
Recurring revenue model
AHC's mix of product sales plus project services and ongoing support/subscriptions creates recurring revenue and customer stickiness. That business model smooths cash flows, supports higher lifetime customer value, and enables predictable maintenance and software upsell streams over the medium term.
Negative Factors
Margin compression
A sharp decline in net margin erodes the company's ability to convert revenue into reinvestable cash. If higher costs or pricing pressure persist, profitability headwinds could limit funding for product development, sales expansion, and long‑term margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue model
AHC's mix of product sales plus project services and ongoing support/subscriptions creates recurring revenue and customer stickiness. That business model smooths cash flows, supports higher lifetime customer value, and enables predictable maintenance and software upsell streams over the medium term.
Read all positive factors

Austco Healthcare Limited (AHC) vs. iShares MSCI Australia ETF (EWA)

Austco Healthcare Limited Business Overview & Revenue Model

Company Description
Austco Healthcare Limited, together with its subsidiaries, engages in the manufacture, distribution, marketing, supply, service, and sale of healthcare and electronic communications systems in Australia, New Zealand, Asia, Europe, and North Americ...
How the Company Makes Money
AHC makes money primarily by selling and deploying clinical communication and nurse call systems to healthcare providers. Revenue is generated from (1) product and system sales (including hardware and software components delivered as part of a sit...

Austco Healthcare Limited Financial Statement Overview

Summary
Solid overall fundamentals: strong revenue growth (+12.72%) and a healthy gross margin (52.05%) support profitability. Balance sheet strength is a key positive with very low leverage (debt-to-equity 0.075) and a solid equity base (equity ratio 56.79%). Main concern is profitability pressure, with net margin down to 7.29% from 12.17%, and free cash flow growth slowing to 5.13%.
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue92.73M81.41M58.15M41.98M35.88M31.25M
Gross Profit34.91M42.37M30.67M6.68M18.85M16.71M
EBITDA13.87M11.10M8.11M3.60M3.73M5.01M
Net Income7.75M5.93M7.08M2.26M2.33M3.42M
Balance Sheet
Total Assets87.50M91.07M68.70M37.85M34.03M27.18M
Cash, Cash Equivalents and Short-Term Investments15.23M14.48M13.56M4.67M7.63M7.77M
Total Debt7.68M3.88M1.78M524.00K979.00K1.15M
Total Liabilities28.76M39.34M24.33M12.85M10.94M7.88M
Stockholders Equity58.76M51.73M44.38M25.00M23.09M19.30M
Cash Flow
Free Cash Flow17.39M10.66M7.45M-1.25M315.00K1.91M
Operating Cash Flow20.36M13.42M11.35M320.00K1.94M3.21M
Investing Cash Flow-14.00M-12.32M-11.06M-1.57M-1.63M-1.30M
Financing Cash Flow-1.08M-402.00K8.84M-1.58M-312.00K-474.00K

Austco Healthcare Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.34
Price Trends
50DMA
0.36
Negative
100DMA
0.38
Negative
200DMA
0.37
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
44.34
Neutral
STOCH
51.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHC, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.35, below the 50-day MA of 0.36, and below the 200-day MA of 0.37, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 51.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AHC.

Austco Healthcare Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
AU$127.42M7.7014.03%39.98%-30.04%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
AU$3.42B-3.16-890.76%55.91%22.60%
47
Neutral
AU$61.04M-59.43-1.32%7.38%82.39%
44
Neutral
AU$99.06M-6.27-54.48%34.20%-23.90%
43
Neutral
AU$69.45M-6.64-59.96%
42
Neutral
AU$84.50M-14.80-40.65%700.00%26.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:AHC
Austco Healthcare Limited
0.34
0.05
17.24%
AU:CYC
Cyclopharm Limited
0.82
-0.42
-33.87%
AU:SHG
Singular Health Group Ltd
0.22
-0.01
-4.35%
AU:TRJ
Trajan Group Holdings Ltd
0.40
-0.38
-48.72%
AU:4DX
4DMedical Ltd
5.95
5.69
2188.46%
AU:ALA
Arovella Therapeutics Limited
0.07
>-0.01
-10.26%

Austco Healthcare Limited Corporate Events

Austco Director Shifts Shareholdings to Indirect Holding Structure
Mar 3, 2026
Austco Healthcare has disclosed a change in the shareholdings of director James Brett Francis Burns, reflecting an internal rebalancing of his direct and indirect interests. Burns disposed of his directly held shares while increasing his indirect ...
Austco Healthcare Cancels 393,946 Performance Rights After Conditions Not Met
Jan 6, 2026
Austco Healthcare Limited has announced the cessation of 393,946 performance rights, which lapsed on 5 January 2026 because the conditions attached to these rights were not met or became incapable of being satisfied. The lapse of these conditional...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 07, 2026